Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Novavax is a clinical-stage biopharmaceutical company developing novel recombinant vaccines using proprietary Virus-Like Particle (VLP) technology. The company focuses on pandemic and seasonal influenza (H1N1, H5N1), Respiratory Syncytial Virus (RSV), and Varicella Zoster Virus (VZV). The company has not yet commercialized any products and relies on research contracts, government grants, and equity financing.
Key Financial Metrics
| Metric (in thousands) | 2009 | 2008 |
|---|---|---|
| Revenue | $325 | $1,064 |
| Net Loss | $(38,374) | $(36,049) |
| Loss Per Share (Basic & Diluted) | $(0.45) | $(0.53) |
| Cash and Cash Equivalents | $38,757 | $26,938 |
| Short-Term Investments | $4,193 | $6,962 |
| Working Capital | $36,476 | $7,379 |
| Accumulated Deficit | $(274,150) | $(235,776) |
| Long-Term Debt | $406 | $480 |
Note: The company extinguished $22 million in senior convertible notes during 2009 through a combination of cash payments and stock issuance.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 69% to $0.3 million in 2009 from $1.1 million in 2008, primarily due to the timing of work under government contracts.
- Increased Operating Expenses: Total operating expenses rose to $37.7 million in 2009 from $35.4 million in 2008. Research and Development (R&D) expenses increased by 6% to $25.8 million, driven by clinical trials for H1N1 and seasonal influenza candidates.
- Investment Impairments: The company recorded a $1.3 million impairment charge on auction rate securities in 2009, partially offset by $0.8 million in realized gains from redemptions.
- Capital Raising: Net proceeds from equity financing were significant in 2009, including an underwritten public offering ($21 million), At-the-Market sales ($22 million), and a stock purchase agreement with Cadila Pharmaceuticals ($10.6 million).
- Liquidity Improvement: Cash and cash equivalents increased by $11.8 million year-over-year, bolstered by financing activities which provided $42.3 million in net cash.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- H1N1 Progress: Novavax reported positive results from the first stage of a Phase I/II clinical trial for its H1N1 vaccine in Mexico and filed for regulatory approval there. A second stage involving 3,000 subjects was fully enrolled.
- Seasonal Influenza: Favorable Phase II results in healthy adults supported the commencement of a Phase II dose range study in elderly patients. The company is seeking a contract award from HHS BARDA to fund advanced development.
- Liquidity: Management believes current cash and short-term investment balances ($43 million total) are sufficient to fund operations for at least the next twelve months. However, additional capital will be required for future clinical development and commercialization.
Risks and Contingencies
- History of Losses: The company has incurred losses since inception with an accumulated deficit of $274.2 million. There is no assurance of future profitability.
- Capital Markets: Access to capital is critical. Volatility in credit and equity markets could restrict the company's ability to raise funds on acceptable terms.
- Investment Liquidity: $5.1 million of par value in auction rate securities (carried at $4.2 million fair value) presents liquidity concerns due to credit market conditions.
- Regulatory Compliance: The company is not currently in compliance with NASDAQ listing requirements regarding the majority of independent directors on the Board of Directors, though a plan to cure this is in progress.
- Related Party Notes: Two former directors have outstanding notes totaling approximately $2.0 million (principal and interest) which are in default. The company is pursuing collection but recovery is uncertain.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $43 million cash position against the projected burn rate for upcoming Phase III trials and manufacturing scale-up.
- H1N1 Regulatory Status: Monitor the status of the regulatory approval application in Mexico and the results of the ongoing Phase II clinical trials.
- Government Funding: Track the outcome of the HHS BARDA request for proposal (RFP) for advanced development of recombinant influenza vaccines.
- Auction Rate Securities: Assess the liquidity risk and potential further impairment of the $4.2 million investment in auction rate securities.
- NASDAQ Compliance: Confirm the appointment of new independent directors to regain compliance with NASDAQ listing rules.
- Debt Collection: Review the status of legal proceedings regarding the $2.0 million in defaulted notes from former directors.